Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus

Horm Metab Res. 1997 Sep;29(9):411-6. doi: 10.1055/s-2007-979067.

Abstract

Studies examining small groups of type 2-(NIDDM) diabetic patients have shown the potential of glucagon-like peptide 1 (GLP-1) to normalize fasting hyperglycaemia. Patient characteristics determining the size of the effect have not been reported. Therefore, the results of four studies were analysed. Exogenous GLP-1 was administered i.v. or s.c. in 37 type 2-diabetic patients, age 60 +/- 8 years; BMI 28.2 +/- 5.3 kg/m2; HbA1c 10.6 +/- 1.6%; diabetes duration 10 +/- 6 years, treatment with sulfonylureas, n = 33, metformin, n = 11, acarbose, n = 3. Results were analysed using repeated measures analysis of variance and multiple regression analysis. Exogenous GLP-1 lowered fasting plasma glucose within 4-5 h from 12.8 +/- 2.5 to 5.3 +/- 1.3 mmol/l (placebo: 12.8 +/- 2.3 to 10.0 +/- 2.2; p < 0.0001 for the interaction of treatment and time). Only fasting glycaemia (p = 0.0085) and the route (i.v. vs. s.c.; p = 0.05), but not gender, age, BMI, HbA1c, diabetes duration, treatment with sulfonylureas, metformin or acarbose, were significant predictors of the plasma glucose concentrations reached after the administration of GLP-1 (variation: 3.4-8.5 mmol/l). In conclusion, GLP-1 is able to normalize plasma glucose in all type 2-diabetic patients studied. This analysis underlines the great therapeutic potential of GLP-1.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acarbose
  • Aged
  • Blood Glucose / metabolism
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Glucagon / administration & dosage
  • Glucagon / therapeutic use*
  • Glucagon-Like Peptide 1
  • Glycated Hemoglobin A / metabolism
  • Humans
  • Metformin / therapeutic use
  • Middle Aged
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / therapeutic use*
  • Protein Precursors / administration & dosage
  • Protein Precursors / therapeutic use*
  • Regression Analysis
  • Sulfonylurea Compounds / therapeutic use
  • Trisaccharides / therapeutic use

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Peptide Fragments
  • Protein Precursors
  • Sulfonylurea Compounds
  • Trisaccharides
  • Glucagon-Like Peptide 1
  • Glucagon
  • Metformin
  • Acarbose